Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia

BMJ Open

Volumn 4, Issue 7, 2014, Pages

  MacDonald, Thomas M ^a   Ford, Ian ^b   Nuki, George ^c   Mackenzie, Isla S ^a   De Caterina, Raffaele ^d   Findlay, Evelyn ^a   Hallas, Jesper ^e   Hawkey, Christopher J ^f   Ralston, Stuart ^c   Walters, Matthew ^b   Webster, John ^g   McMurray, John ^b   Ruiz, Fernando Perez ^h   Jennings, Claudine G ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF CHIETI   (Italy)

^e UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g UNIVERSITY OF ABERDEEN   (United Kingdom)

^h HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; DICLOFENAC; FEBUXOSTAT; MELOXICAM; NAPROXEN; URATE; ANTIGOUT AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; DENMARK; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEMALE; FOLLOW UP; GOUT; HEART ARREST; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MORTALITY; OPEN STUDY; OPTIMAL DRUG DOSE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; REVASCULARIZATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS; URIC ACID BLOOD LEVEL; VEIN THROMBOSIS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL;

ALLOPURINOL; CARDIOVASCULAR DISEASES; FEBUXOSTAT; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; PROSPECTIVE STUDIES; RESEARCH DESIGN;

EID: 84904264420     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005354     Document Type: Article

References (19)

1. Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Managed Care 2005;11:S435-42. (Pubitemid 41722200)
2. Annemans L, Spaepen E, Gaskin M, et al. Ice 2000-2005. Ann Rheum Dis 2008;67:960-6.
3. Smith EUR, Diaz-Torne C, Perez-Ruiz F, et al. Epidemiology of gout: an update. Best Pract Res Clin Rheum 2010;24:811-27.
4. Kuo C-F, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis Published Online First: 15 Jan 2014. doi:10.1136/annrheumdis-2013-204463
5. Wortmann R. Kelly's textbook of rheumatology. 8th edn. Philadelphia: Saunders, 2009.
6. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21.
7. Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease. Arthritis Rheum 2008;58:623-30.
8. Strasak AM, Kelleher CC, Brant LJ, et al. Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008;125:232-9.
9. Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83 683 Austrian men. Clin Chem 2008;54:273-84. (Pubitemid 351302628)
10. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2005;377:165-77.
11. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-24. (Pubitemid 44620440)
12. Committee JF. British national formulary. 63rd edn. London: BMJ Group and Pharmaceutical Press, 2012.
13. Pal B, Foxall M, Dysart T, et al. How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheum 2000;19:21-5. (Pubitemid 30123236)
14. Schumacher HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, Phase III, Randomized, Double-Blind, Parallel-Group Trial. Arthritis Rheum 2008;59:1540-8.
15. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Pressure 1992;1:113-19.
16. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;64:1447-61.
17. Evans JMM, MacDonald TM. Record-linkage for pharmacovigilance in Scotland. Br J Clin Pharmacol 1999;47:105-10. (Pubitemid 29043172)
18. No authors listed. Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
19. ISPE ISfP. Guidelines for good pharmacoepidemiology practices (GPP), 2007.